ENTITY
3SBio

3SBio (1530 HK)

196
Analysis
Health Care • China
3SBio is a leading biotechnology company engaged in the research, development, manufacturing, and marketing of biopharmaceutical products. The company's diverse portfolio addresses therapeutic areas such as nephrology, oncology, supportive cancer care, inflammation, infectious diseases, autoimmune diseases, metabolism, and dermatology, with key products including EPIAO and TPIAO. 3SBio was founded in 1993 and is headquartered in Shenyang, China.
more
•20 Jul 2019 11:52

Hong Kong Short Reporting - Insights from 12 July Data

We analyse the latest SFC data released last evening on short position reporting in Hong Kong for the week ended 12 July.Total short notional in...

Logo
588 Views
Share
•19 Jul 2019 11:28

SinoMab (中国抗体): Pipeline Concentrated on Autoimmune Therapy

SinoMab, the first Hong Kong-headquartered biotech company coming to list on the SEHK, plans to raise USD100 to 200 million.  In this insight, we...

Logo
975 Views
Share
•03 Jun 2019 04:21

Hansoh Pharma IPO: Valuation Reasonable for the Trade-Offs

Hansoh Pharmaceutical (3692 HK) claims to be one of the few R&D driven Chinese pharmaceutical companies. It announced its IPO price range of...

Logo
878 Views
Share
•23 May 2019 09:44

Hansoh Pharma (翰森制药) IPO: Thoughts on Valuation

Hansoh Pharma has started pre-marketing its IPO to raise USD 1bn in its IPO. In our previous insights, we covered the company's major products and...

Logo
971 Views
Share
bearish•Mabpharm
•17 May 2019 15:58

MabPharm (迈博医药) IPO: Fairly Valued and Lacks Biotech Investors

MabPharm, a biotech company backed by CDH Investment, launched book building today. In our previous insights, we have discussed the company's...

Logo
763 Views
Share
x